International Journal of Mental Health and Addiction
May 5, 2026
Cerina Dubois, Amrit Baral, Riana Durrett et al.
An emerging approach called California Sober (CS) has gained attention for promoting abstinence of all intoxicating substances except cannabis and potentially, psychedelics. Cannabis legalization and the expansion of cannabis products have introduced new complexities in addiction recovery, challenging traditional abstinence-based frameworks such as Alcoholics Anonymous (AA), which define...
Sleep
May 1, 2026
Denise C. Vidot, Bria-Necole Diggs, Amrit Baral et al.
Abstract Introduction Psychedelic use and interest in its therapeutic potential are rapidly increasing; yet its relationship with insomnia remains poorly understood. This study aims to estimate differences in insomnia severity by type of psychedelic consumed among a cohort of 18-to-35-year olds. Methods Data are from the Herbal Heart Study - Sleep Ancillary (N=100) cannabis consumers....
Cancer causes & control : CCC
April 22, 2026
Amrit Baral, Yue Pan, Wayway M. Hlaing et al.
To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors. We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n =...
Scientific Reports
December 8, 2025
Amrit Baral, Yue Pan, Wayway M. Hlaing et al.
Prostate cancer is the second leading cause of cancer-related deaths among U.S. men. While cannabis and classic psychedelics gain attention for symptom management in oncology, their associations with prostate cancer remain unexplored. This study evaluates associations between lifetime classic psychedelic and cannabis use with prostate cancer diagnoses among older U.S. adults using 2015-2019...
Sleep
May 1, 2025
Denise C. Vidot, Amrit Baral, Bria-Necole Diggs et al.
Abstract Introduction Research on psychedelic use and sleep satisfaction remains unclear despite increased use. This study examines the psychedelic use and sleep satisfaction among 18-to-35-year-olds enrolled in the Herbal Heart Study. Methods The exposure variables were lifetime self-reported use of any psychedelic (LSD, psilocybin, peyote, mescaline, ayahuasca/DMT) and psilocybin-alone. Sleep...
Journal of Clinical Oncology
June 1, 2024
Amrit Baral, Yue Pan, Alberto J. Caban Martinez et al.
e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest known psychedelic, yet underexplored in clinical research. Preclinical studies suggest its extract stimulates lymphocyte proliferation, kills tumor cells, and may regulate sleep. This study aims to estimate the prevalence of classic psychedelic use among...